QID 352252

Date Published: 2021-03-25

QID 352252: Amazon Linux Security Advisory for bind: ALAS2-2021-1614

<DIV> Issue Overview:

A buffer overflow flaw was found in the SPNEGO implementation used by BIND. This flaw allows a remote attacker to cause the named process to crash or possibly perform remote code execution. The highest threat from this vulnerability is to confidentiality, integrity, as well as system availability. (CVE-2020-8625 )

</DIV>

Allows unauthorized disclosure of information; allows unauthorized modification; allows disruption of service.

  • CVSS V3 rated as Critical - 8.1 severity.
  • CVSS V2 rated as High - 6.8 severity.
    • Solution
    Please refer to Amazon advisory ALAS-2021-1614 for affected packages and patching details, or update with your package manager.
    Vendor References

    CVEs related to QID 352252

    CVE-2020-8625 |
    Software Advisories
    Advisory ID Software Component Link
    ALAS-2021-1614 Amazon Linux 2 bind (9.11.4-26.P2.amzn2.4) on aarch64 URL Logo alas.aws.amazon.com/AL2/ALAS-2021-1614.html
    ALAS-2021-1614 Amazon Linux 2 bind (9.11.4-26.P2.amzn2.4) on i686 URL Logo alas.aws.amazon.com/AL2/ALAS-2021-1614.html
    ALAS-2021-1614 Amazon Linux 2 bind (9.11.4-26.P2.amzn2.4) on noarch URL Logo alas.aws.amazon.com/AL2/ALAS-2021-1614.html
    ALAS-2021-1614 Amazon Linux 2 bind (9.11.4-26.P2.amzn2.4) on src URL Logo alas.aws.amazon.com/AL2/ALAS-2021-1614.html
    ALAS-2021-1614 Amazon Linux 2 bind (9.11.4-26.P2.amzn2.4) on x86_64 URL Logo alas.aws.amazon.com/AL2/ALAS-2021-1614.html
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].